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1. Acute exacerbations of chronic bronchitis - the role of moxifloxacin and 
other new fluoroquinolones 
A. ANZUETO AND G. TILLOTSON” 
Audie Murphy VA Hosp, San Antonio, Texas and “Bayer Corporation, West Haven CT., US.A. 
In recent years, extensive efforts have been made to develop new fluoroquinolones with improved activities against Gram- 
positive organisms, such as S. pneumoniue. The role of moxifloxacin, an 8-methoxyquinolone, for the treatment of acute 
bacterial exacerbations of chronic bronchitis (AECB) is reviewed. Moxifloxacin is highly active against H in&enzae, the most 
common pathogen associated with AECB, and shows excellent in vitro activity against the other major pathogens, M. 
catarrhalis, S. pneumoniae, and minor pathogens. Moxifloxacin’s in vitro antibacterial activity against Gram-positive bacteria 
is significantly better than that of ciprofloxacin, levofloxacin or sparfloxacin. In comparative trials involving commonly used 
treatment regimens, moxifloxacin (400mg daily for 5d) achieved bacteriologic and/or clinical success rates of approximately 
90% or higher. Moxifloxacin had a higher eradication rate for the four most commonly isolated pathogens (95%) compared to 
clarithromycin and cefuroxime (87% and 83% respectively). The clinical success rate of moxifloxacin 400mg daily for 5 days 
(93O%) was identical to that of the comparator, co-amoxiclav, three times daily for 7 days (91%). Fluoroquinolones have a good 
clinical success rate in the treatment of AECB, but are rarely considered first-line agents because of perceived low efficacy 
against S. pneumoniae. With its good tissue penetration, safety profile and excellent activity against all common respiratory 
pathogens, moxifloxacin is an effective, safe and well tolerated option in the treatment of acute exacerbations of chronic 
bronchitis. Moxifloxacin carries the advantage of once-daily dosing and short treatment duration (5 days). 
2. Epidemiological variables within a protocol of surveillance anti-TBC toward 
social and healthy operators working in geriatric institute 
I? BERARDINELLI”, G. CAL@, E. CAROTENUTO”, M. BATTAGLIERI? A. CAMPISI$ 
I? DE LUCAS, M. MONTI~, M. CORCELLP, D. POMES~, E. ROMAJI AND M. BETTIII 
*Physiopath & Chest Rehabil. L? + IlSpecialist Visitors, $§Prev. Medic. U (f’§Nurses) and Healthy 
Activities Management, I? A. TRIVULZIO Rehabil. Geriatric Instit., Milan, Italy 
Preventing TBC is still a compulsory goal in all countries but guidelines are not easy to follow because of many social, 
individual and legal obstacles also rising from people’s mobility. For over 10 years we have been carrying out an epidemio- 
logical surveillance anti-tubercular programme to study the immunitary condition toward Koch’s bacillus in the population 
represented by social-healthy operators. The idea about this study comes out from the observation of the various kind of 
healthy operators working in our Institute and from the consideration that most of these figures are not common in other 
ones. We studied 745 subjects, employed in our Institute from 1996 to 1999. Mostly the Mantoux’ s intradermo reaction- 
negative (IDR Mtx) operators refused the anti-tubercular vaccination (as shown in the following table). We think that the 
different,kind of answers to proposal of the antitubercular vaccination depends on some variables: 
(1) knowledge about the pathology; 
(2) cultural level; 
(3) civic conscience about general health; 
(4) title of the study; 
(5) temporary work that does not permit subjects to be followed with time. 
Our data show many difficulties preventing the achiement of an effective anti-tubercular surveillance program. 
3. Cefodizime enhances phagocytosis and intracellular killing of Staphylococcus 
aweus but does not influence polymorphonuclear leukocytes response 
to FMLP stimulation 
I? BIALASIEWICZ, R. STOLAREK, I? WEJNER, G. PIASECKA, B. DUTKIEWICZ”, 
J. MIKUCKI” AND D. NOWAK 
Dept. of Physiology, “Dept. of Microbiology, Medical University of Lodz, Poland 
Polymorphonuclear leukocytes (PMNL) are key defence cells against bacterial and fungal infections. Cefodizime (CDZ) - an 
aminothiazolylcephalosporin - has been reported to favourably influence immunodefense in chronic diseases (eg. diabetes, 
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TABLE 
Workers Qua1 All cases IDRMtx + IDRMtx - BCG + BCG - 
Geriatri Oprs 
Ordelaies 
Nurses 
Aides Nrs 
Educators 
Physicians 
RadiolTech 
Past workrs 
Volunteers 
Social 
Chsts therpst 
Total 
56 28.6% 
148 20% 
268 30% 
7 14% 
10 20% 
81 30% 
2 50% 
5 0% 
107 10% 
6 0% 
55 26% 
745 
71.4% 
80% 
70% 
86% 
80% 
70% 
50% 
100% 
90% 
100% 
74% 
33.3% 
25% 
65% 
16.6% 
25% 
46.5% 
50% 
0% 
0% 
50% 
55.5% 
66.7% 
75% 
35% 
83.4% 
75% 
53.5% 
0% 
100% 
100% 
50% 
44.5% 
BCG+ : subjects vaccinated BCG-: subjects non vaccinated 
uremia) mechanism thereof remains obscure. Therefore, the aim of the study was to assess the effect of CDZ on in vitro 
activity of PMNL from healthy volunteers. PMNL (2~1O-~/ml) were incubated for lh with CDZ (high therapeutic 
concentration - 100 mg/l) and then intracellular calcium concentration ([Ca’+]i) changes, chemiluminescence and production 
of hydrogen peroxide upon fMLP stimulation (10m7M) were measured. To assess bactericidal capacity of PMNL tests for 
phagocytosis and intracellular killing of St. aureus were performed. 
In PMNL preincubated with CDZ enhanced phagocytosis (ie the number of St. aureus colonies cultured from lysed 
PMNL) was observed - (M-0.8x2106, QR-2.2x 106) versus control (M-0.52x106, QR-1.46~10~) (n=12, PcO.05). The 
intracellular killing (percentage of killed phagocytosed bacteria to all phagocytosed bacteria) was 32 x 15 versus 19 x 13% for 
cells preincubated with CDZ and controls, respectively (n=12, PcO.05). We observed no difference in intracellular calcium 
changes, chemiluminescence and hydrogen peroxide production upon fMLP stimulation. In conclusion - enhanced activity of 
preincubated with CDZ PMNL against St. aureus is not related to upregulation of classical activation pathway and 
production of toxic reactive oxygen species and requires further studies. 
4. Bronchial infection and systemic steroid therapy in a sample of patients with acute 
exacerbation of chronic bronchitis (AECB) 
l? BONFITTO, M. A. VALENZA*, G. CASTELLANA, F. GENTILE, I? LOMBARDI, G. RICCO, 
V. LAMORGESE, M. CORREALE” AND A. LIPPOLIS* 
Division of Pneumology, S. Michele M. Laureto Hospital, ASL Bal.5, Putignano (Ba), Italy 
*Laboratory of Bacteriology, I. R. C. C.S. “S.De Bellis”, Castellana Grotte (Ba), Italy 
We enrolled 96 consecutive patients (62 M and 34 F, aged 71 yrs), 65 hospitalized and 31 outpatients, evaluated at our 
Division of Pneumology for AECB. No patient had received any systemic antibiotic during the time period extending 30 days 
prior to enrohnent. We did not enrol patients with diagnosis of pneumonia, bronchiectasis, cystic fibrosis and other bronchial 
infection apart from chronic bronchitis, patients with previously diagnosed diseases of immune function and patients with 
neoplastic diseases. All the enrolled patients showed an increase of dyspnea, cough and sputum volume or a change in 
character of sputum. The patients had an obstructive respiratory pattern (FVC%pred 68.5; FEVl%pred 54.9; FEVl/FVC 
61.56%); thirty-nine patients had acute or chronic respiratory failure. 
We obtained 96 samples of sputum after cleaning the mouth with saline solution and we evaluated them with Gram stain to be 
sure that polymorphonuclear/epithelial cells ratio (Bartlett index) confirmed the provenience from the lower respiratory tract. In 
50 patients (52%) it was possible to perform an etiological diagnosis (more pathogen agents were isolated from 21 patients): B. 
catarrhalis (24%); C. albicans (24%); Enterobacter spp (2%); H. influenzae (40%); Klebsiella spp (4%); l? aeruginosa (10%); S. 
aureus (6%); Streptococcus spp (8%); S. pneumoniae (28%); other bacteria (10%). Thirty-four (68%) out of these 50 patients 
reported frequent use of systemic steroid therapy on the occasion of several episodes of AECB during the previous year. 
